Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pharmaids Pharmaceuticals filed its 36th Annual Report for FY 2024-25 along with the AGM notice. The 36th AGM is scheduled for September 23, 2025, with remote e-voting from September 19–22, 2025. On a standalone basis, revenue grew to ₹335.98 Lakhs (from ₹82.27 Lakhs), but the net loss widened to ₹727.92 Lakhs (from ₹494.98 Lakhs). On a consolidated basis, revenue rose to ₹1,955.14 Lakhs (from ₹1,599.03 Lakhs) while the net loss stood at ₹1,350.51 Lakhs (from ₹1,184.31 Lakhs). The Board did not recommend any dividend. The report highlights a change in management control following an open offer completed on August 18, 2025, where Chairman Dr. S. N. Vinaya Babu and PAC acquired promoter status. The Company also proposed selling its Tumkur land parcel for ₹16.5 Crore to the Chairman and divesting its 66.5% stake in Anugraha Chemicals for ₹10.5 Crore to generate liquidity.
Shareholders should note that despite revenue growth, the Company continues to post losses on both standalone and consolidated bases, with no dividend declared. The open offer and management control change, along with proposed asset sales to the Chairman, may raise governance concerns but are aimed at improving liquidity for the CRDMO business transition. Investors should review the full annual report for details before the AGM.